Walter V. Klemp - Jul 2, 2022 Form 4/A - Amendment Insider Report for Moleculin Biotech, Inc. (MBRX)

Role
CEO and President, Director
Signature
/s/ Jonathan P. Foster by Power
Stock symbol
MBRX
Transactions as of
Jul 2, 2022
Transactions value $
-$5,268
Form type
4/A - Amendment
Date filed
7/15/2022, 08:04 PM
Date Of Original Report
Jul 6, 2022
Previous filing
Jul 15, 2022
Next filing
Jul 15, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MBRX Common Stock Options Exercise +14.7K +6.96% 226K Jul 2, 2022 Direct F1
transaction MBRX Common Stock Tax liability -$5.27K -3.58K -1.59% $1.47 222K Jul 2, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MBRX Restricted Stock Units Options Exercise $0 -14.7K -1.31% $0.00 1.11M Jul 2, 2022 Common Stock 14.7K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 Shares withheld for payment of taxes upon vesting of restricted stock unit awards.
F3 On July 2, 2020, the reporting person was granted 58,869 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

Remarks:

Filed solely to correct the amount in Table II, Column 9, from 1,383,145 to 1,111,145.